10x Genomics (TXG) and French TechBio startup Cure51 announced that Cure51 will deploy 10x Genomics’ Visium HD as part of its pioneering work to understand the unique biology of exceptional cancer survivors, whose survival mechanisms could hold the key to new therapeutic approaches. Working alongside more than 50 medical institutions, Cure51 intends to collect and analyze tumor tissues from over 1,000 exceptional cancer survivors across 40 countries in the next 18 months. 10x Genomics’ Visium HD assay, launched earlier this year, enables researchers to perform whole transcriptome spatial gene expression analysis at single cell-scale resolution. The assay will enable Cure51’s scientific and biocomputational teams and partners to generate spatial molecular profiling of tumor samples at single cell-scale resolution and gain insights into the complex interactions between the tumor cells and their microenvironment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10X Genomics CEO Serge Saxonov Initiates Rule 10b5-1 Trading Plan Amid Strategic Financial Maneuvering
- 10x Genomics price target lowered to $23 from $35 at Citi
- 10x Genomics Reports Mixed Q3 2024 Results
- Closing Bell Movers: Alphabet up over 5% on Q3 earnings beat
- 10x Genomics Navigates Revenue Dip with New Launches